产品名称 Suprafenacine - SRF
产品货号 Axon 2398 CAS [1477482-50-0] MF C16H18N4OMW 282.34 Purity: 99% Soluble in DMSO Description Destabilizer of microtubules (IC50 value 0.38 µM for microtubule polymerization inhibition) that causes cell cycle arrest in the G2/M phase and cell death by apoptosis. Suprafenacine (SRF) was found to selectively inhibit cancer cell proliferation (IC50 values 83 - 381 nM in various cancer cell lines) and was effective against drug-resistant cancer cells by virtue of its ability to bypass the multidrug resistance transporter P-glycoprotein (P-gp). References Certificates Categories Extra info B.H. Choi et al. Suprafenacine, an indazole-hydrazide agent, targets cancer cells through microtubule destabilization. PLoS One. 2014 Oct 29;9(10):e110955. Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Cycle Regulation Cell Signaling & Oncology Tubulin Destabilizer of microtubules that causes cell cycle arrest in the G2/M phase Chemical name (E)-N'-(4-methylbenzylidene)-4,5,6,7-tetrahydro-1H-indazole-3-carbohydrazide Parent CAS No. [1477482-50-0] Order Size Unit Price Stock 10 mg €110.00 In Stock
产品价格 现货询价,电话:010-67529703
产品规格
产品品牌 axonmedchem
产品概述
产品详情

Suprafenacine - SRF

Based on 12 reference(s) in Google Scholar 9 10 12

Axon 2398

CAS [1477482-50-0]

MF C16H18N4O
MW 282.34

  • Purity: 99%
  • Soluble in DMSO

Suprafenacine

Description

Destabilizer of microtubules (IC50 value 0.38 µM for microtubule polymerization inhibition) that causes cell cycle arrest in the G2/M phase and cell death by apoptosis. Suprafenacine (SRF) was found to selectively inhibit cancer cell proliferation (IC50 values 83 - 381 nM in various cancer cell lines) and was effective against drug-resistant cancer cells by virtue of its ability to bypass the multidrug resistance transporter P-glycoprotein (P-gp).
产品资料